Australija - engleski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - mycoplasma hyopneumoniae strain j; thiomersal - misc. vaccines or anti sera - mycoplasma hyopneumoniae strain j vaccine-general active 1.0 rp; thiomersal mercury other 0.01 mg/ml - immunotherapy - pigs | boar | gilt | piglet | sow | swine - mycoplasma hyopneumoniae | reduction of lung lesions | respiratory disease | swine enzootic pneumonia

Australija - engleski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - mycoplasma hyopneumoniae - inactivated antigen; thiomersal - misc. vaccines or anti sera - mycoplasma hyopneumoniae - inactivated antigen vaccine-general active 31600.0 ru/2ml; thiomersal mercury other 0.1 mg/ml - immunotherapy - pigs | boar | gilt | piglet | sow | swine - mycoplasma hyopneumoniae | pneumonia | bacterial pneumonia | reduction of lung lesions | respiratory disease | swine enzootic pneumonia

Španjolska - španjolski - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

merck sharp & dohme animal health s.l. - mycoplasma hyopneumoniae (cepa attc nº 25934) - emulsiÓn inyectable - mycoplasma hyopneumoniae (cepa attc nº 25934) minimo 1,47 - mycoplasma - cerdos de engorde

Španjolska - španjolski - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

elanco gmbh - mycoplasma hyopneumoniae inactivado, cepa nl 1042 - emulsiÓn inyectable - mycoplasma hyopneumoniae inactivado, cepa nl 1042 3,7 log10 - mycoplasma - lechones

Australija - engleski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - m. hyopneumoniae - inactivated whole cell culture; thiomersal - misc. vaccines or anti sera - m. hyopneumoniae - inactivated whole cell culture vaccine-general active 6000.0 ru/do; thiomersal mercury other 0.1 mg/ml - immunotherapy - pigs | boar | gilt | piglet | sow | swine - mycoplasma hyopneumoniae | vaccine | equine rotavirus | reduction of lung lesions | respiratory disease | swine enzootic pneumonia

Australija - engleski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - inactivated mycoplasma hyopneumoniae strain j - unknown - inactivated mycoplasma hyopneumoniae strain j vaccine - general active 0.0 - immunotherapy

Europska Unija - malteški - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - majjali - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Europska Unija - finski - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - siat - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Europska Unija - hrvatski - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - svinje - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Europska Unija - latvijski - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - cūkas - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.